Recombinant glucocerebrosidase
Pregnancy: Available data on use in pregnant women include more than 300 pregnancies from the pharmacovigilance database and published observational cohort studies, including the international Gaucher Disease registry. While these data cannot definitively establish or exclude a velaglucerase alfa associated risk, they have not identified an association with major birth defects, miscarriage, or adverse maternal or fetal outcomes. No fetal harm was observed in rats or rabbits at exposures up to 1.8 and 4.3 times the recommended human daily dose. Note that women with type 1 Gaucher disease have an increased disease-associated risk of spontaneous abortion, especially if disease symptoms are not controlled.
Velaglucerase alfa
Brand names: VPRIV
Velaglucerase alfa is a recombinant enzyme replacement therapy given by intravenous infusion for type 1 Gaucher disease.
Auto-extracted from the source labelling — not yet independently clinician-verified. These values were distilled from the UK SPC (or the US label where noted) but have not had a clinician sign-off. Confirm against the current SmPC before prescribing.
Adult dose
Dose:60 Units/kg — recommended starting dosage in adults naive to enzyme replacement therapy (type 1 Gaucher disease).
Route: Intravenous infusion over 60 minutes — reconstitute the lyophilised powder with Sterile Water for Injection (giving 100 Units/mL), then dilute the calculated dose in 100 mL of 0.9% sodium chloride injection and administer through an in-line low protein-binding 0.2 or 0.22 micrometre filter
Frequency: Every other week (every 2 weeks)
SOURCE: US FDA prescribing information (VPRIV, Takeda Pharmaceuticals America, label date 2024-11-26) via openFDA/DailyMed — NO UK SPC was present in the fetched bundle; clinician to cross-check against the UK SPC. UNITS ARE 'UNITS PER KG', NOT MILLIGRAMS. The 60 Units/kg starting dosage applies to naive adults AND naive paediatric patients 4 years of age and older. The dosage can be adjusted based on achievement and maintenance of each patient's therapeutic goals. SWITCHING FROM IMIGLUCERASE: adults and paediatric patients 4 years of age and older currently on a stable dosage of imiglucerase for type 1 Gaucher disease may be switched by starting velaglucerase alfa at the PREVIOUS IMIGLUCERASE DOSAGE, two weeks after the last imiglucerase dose, given as a 60-minute intravenous infusion. ADMINISTRATION SETTING: administration should be supervised by a healthcare provider knowledgeable in the management of hypersensitivity reactions including anaphylaxis; initiate in a healthcare setting with appropriate medical monitoring and support measures, including access to cardiopulmonary resuscitation equipment (boxed warning covers life-threatening hypersensitivity reactions including anaphylaxis). PREMEDICATION: consider pre-treatment with antihistamines and/or corticosteroids in patients who exhibited symptoms of hypersensitivity with prior velaglucerase alfa infusions. PREPARATION: determine the number of vials from the patient's actual weight and prescribed dose; inject 4.3 mL Sterile Water for Injection per vial and mix gently (DO NOT SHAKE) to give 400 Units in 4 mL (100 Units/mL); use immediately or store the reconstituted or diluted solution for up to 24 hours at 2 to 8 degrees C, protected from light and not frozen, completing the infusion within 24 hours of reconstitution. Slight flocculation is acceptable; do not use if discoloured or if foreign particulate matter is present. Do not infuse with other products in the same infusion tubing (compatibility not evaluated). Vials are single-use, one patient only. Clinical studies used doses ranging from 15 Units/kg to 60 Units/kg every other week. ELDERLY: dose selection should be approached cautiously, considering potential comorbid conditions.
Paediatric dose
Dose:60 Units/kg
Route: Intravenous infusion over 60 minutes (diluted in 100 mL of 0.9% sodium chloride, through an in-line low protein-binding 0.2 or 0.22 micrometre filter)
Frequency: Every other week (every 2 weeks)
Max: Not stated in source
UNIT IS UNITS PER KG, NOT MILLIGRAMS. US label wording (§2.2): 'The recommended starting VPRIV dosage in naive adults and naive pediatric patients 4 years of age and older is 60 Units/kg administered every other week as a 60-minute intravenous infusion.' The dosage can be adjusted based on achievement and maintenance of each patient's therapeutic goals. Paediatric patients 4 years of age and older on a stable imiglucerase dosage may instead be switched at the previous imiglucerase dosage, two weeks after the last imiglucerase dose. Safety and effectiveness have been established for enzyme replacement therapy in patients between 4 and 17 years of age with type 1 Gaucher disease; efficacy and safety have NOT been established in paediatric patients younger than 4 years of age. This is US labelling — clinician to verify against the UK SPC and a children's formulary before use.
Dose auto-extracted from US FDA prescribing information (openFDA / DailyMed) — cross-check; US labelling may differ from UK — not yet clinician-verified. Always confirm against the product SmPC and your local formulary before prescribing.
Paediatric weight-based calculator
UNIT IS UNITS PER KG, NOT MILLIGRAMS. US label wording (§2.2): 'The recommended starting VPRIV dosage in naive adults and naive pediatric patients 4 years of age and older is 60 Units/kg administered every other week as a 60-minute intravenous infusion.' The dosage can be adjusted based on achievement and maintenance of each patient's therapeutic goals. Paediatric patients 4 years of age and older on a stable imiglucerase dosage may instead be switched at the previous imiglucerase dosage, two weeks after the last imiglucerase dose. Safety and effectiveness have been established for enzyme replacement therapy in patients between 4 and 17 years of age with type 1 Gaucher disease; efficacy and safety have NOT been established in paediatric patients younger than 4 years of age. This is US labelling — clinician to verify against the UK SPC and a children's formulary before use.
Hypersensitivity reactions, including anaphylaxis — the most serious and the most commonly observed adverse reactions; commonly reported symptoms were headache, dizziness, hypotension, hypertension, nausea, fatigue/asthenia and pyrexia/increased body temperature, with chest discomfort, dyspnoea, pruritus and vomiting reported post-marketing
Headache and dizziness (>=10%)
Abdominal pain and nausea (>=10%)
Back pain and joint pain (>=10%)
Fatigue/asthenia and pyrexia (>=10%)
Prolonged activated partial thromboplastin time (>=10%)
Clinical monograph
How it works
It replaces deficient beta-glucocerebrosidase activity, catalysing the breakdown of glucocerebroside that otherwise accumulates in macrophages.
Prescribing in practice
Infusion-related and hypersensitivity reactions can occur, so infusions should be given with appropriate monitoring and the infusion rate adjusted or premedication used if reactions develop.
It is administered as a regular intravenous infusion under specialist supervision, typically on an alternating-week schedule.
Antibody formation can develop during treatment and may rarely affect response or tolerability.
Monitoring
Monitor haemoglobin, platelet count, organ volumes, and disease biomarkers periodically to assess treatment response.
Counselling the patient
Report any reaction during or after the infusion, such as flushing, rash, or breathlessness.
Attend regular infusion appointments to maintain disease control.
This treatment manages Gaucher disease but does not cure it, so ongoing therapy is needed.
Evidence & guidelines
Velaglucerase alfa is licensed as enzyme replacement therapy for type 1 Gaucher disease, supported by clinical trial data.
Reference: NICE; SmPC; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing.
The structured dose values shown have been reviewed by a clinician.
Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
